RXi Remains 'Committed and Focused' on RNAi Despite Broadened Focus

RXi's pending acquisition of Apthera will also enable the company to explore the combination of its RNAi technologies with Apthera's peptide know-how, RXi's CEO said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories